{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:54:00Z","timestamp":1781873640081,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-48984-4","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:36:58Z","timestamp":1777084618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishment of a prognostic model for hepatocellular carcinoma patients based on bioinformatics analysis and exploration of prognostic biomarker EPPK1"],"prefix":"10.1038","volume":"16","author":[{"given":"Lingxiu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"48984_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet 391, 1301\u20131314 (2018).","journal-title":"Lancet"},{"key":"48984_CR2","doi-asserted-by":"publisher","first-page":"E183","DOI":"10.1111\/hepr.12942","volume":"48","author":"M Tsukamoto","year":"2018","unstructured":"Tsukamoto, M. et al. Clinical significance of half-lives of tumor markers \u03b1-fetoprotein and des-\u03b3-carboxy prothrombin after hepatectomy for hepatocellular carcinoma. Hepatol. Res.  48, E183\u2013E193 (2018).","journal-title":"Hepatol. Res."},{"key":"48984_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2753.2010.01599.x","volume":"18","author":"M Patel","year":"2012","unstructured":"Patel, M. et al. Hepatocellular carcinoma: Diagnostics and screening. J. Eval. Clin. Pract. 18, 335\u2013342 (2012).","journal-title":"J. Eval. Clin. Pract."},{"key":"48984_CR4","first-page":"498","volume":"75","author":"D Moris","year":"2025","unstructured":"Moris, D. et al. Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians. CA Cancer J. Clin. 75, 498\u2013527 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"48984_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N Engl. J. Med."},{"key":"48984_CR6","doi-asserted-by":"publisher","first-page":"13340","DOI":"10.1074\/jbc.M011386200","volume":"276","author":"F S","year":"2001","unstructured":"S, F. et al. Epiplakin, a novel member of the plakin family originally identified as a 450-kDa human epidermal autoantigen. Structure and tissue localization. J. Biol. Chem. 276, 13340 (2001).","journal-title":"J. Biol. Chem."},{"key":"48984_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s12885-021-08040-y","volume":"21","author":"M D","year":"2021","unstructured":"D, M. et al. KLF5-mediated Eppk1 expression promotes cell proliferation in cervical cancer via the p38 signaling pathway. BMC Cancer. 21, 377 (2021).","journal-title":"BMC Cancer"},{"key":"48984_CR8","doi-asserted-by":"publisher","first-page":"217807","DOI":"10.1016\/j.canlet.2025.217807","volume":"625","author":"H D","year":"2025","unstructured":"D, H. et al. Microbial interactions induce the mutational signature of mismatch repair deficiency in colorectal cancer and associated with EPPK1 mutations. Cancer Lett. 625, 217807 (2025).","journal-title":"Cancer Lett."},{"key":"48984_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin, H. et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature 595, 731\u2013734 (2021).","journal-title":"Nature"},{"key":"48984_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nbt790","volume":"21","author":"B Blagoev","year":"2003","unstructured":"Blagoev, B. et al. A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat. Biotechnol. 21, 315\u2013318 (2003).","journal-title":"Nat. Biotechnol."},{"key":"48984_CR11","doi-asserted-by":"publisher","first-page":"101942","DOI":"10.1016\/j.redox.2021.101942","volume":"41","author":"J Sun","year":"2021","unstructured":"Sun, J. et al. Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation. Redox Biol. 41, 101942 (2021).","journal-title":"Redox Biol."},{"key":"48984_CR12","doi-asserted-by":"publisher","first-page":"102604","DOI":"10.1016\/j.ebiom.2019.102604","volume":"51","author":"Z Qi","year":"2020","unstructured":"Qi, Z. et al. PRAS40 hyperexpression promotes hepatocarcinogenesis. EBioMedicine 51, 102604 (2020).","journal-title":"EBioMedicine"},{"key":"48984_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00018-024-05296-y","volume":"81","author":"C Mo","year":"2024","unstructured":"Mo, C. et al. Epigenetic regulation of DNA repair gene program by hippo\/YAP1-TET1 axis mediates sorafenib resistance in HCC. Cell. Mol. Life Sci. 81, 284 (2024).","journal-title":"Cell. Mol. Life Sci."},{"key":"48984_CR14","doi-asserted-by":"publisher","first-page":"156162","DOI":"10.1016\/j.phymed.2024.156162","volume":"135","author":"H J","year":"2024","unstructured":"J, H. et al. Cepharanthine-mediated endoplasmic reticulum stress inhibits Notch1 via binding GRP78 for suppressing hepatocellular carcinoma metastasis. Phytomedicine 135, 156162 (2024).","journal-title":"Phytomedicine"},{"key":"48984_CR15","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/s41418-018-0059-x","volume":"25","author":"RCL Lo","year":"2018","unstructured":"Lo, R. C. L. et al. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing dishevelled-3 and activating wnt\/\u03b2-catenin pathway. Cell. Death Differ. 25, 1426\u20131441 (2018).","journal-title":"Cell. Death Differ."},{"key":"48984_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12935-018-0704-y","volume":"18","author":"J Yao","year":"2018","unstructured":"Yao, J. et al. Silencing TRIP13 inhibits cell growth and metastasis of hepatocellular carcinoma by activating of TGF-\u03b21\/smad3. Cancer Cell. Int. 18, 208 (2018).","journal-title":"Cancer Cell. Int."},{"key":"48984_CR17","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1158\/0008-5472.CAN-25-0301","volume":"85","author":"RZ Li","year":"2025","unstructured":"Li, R. Z. et al. Hypoxia-induced creatine uptake reprograms metabolism to antagonize PARP1-mediated cell death and facilitate tumor progression in hepatocellular carcinoma. Cancer Res. 85, 3671\u20133688 (2025).","journal-title":"Cancer Res."},{"key":"48984_CR18","first-page":"5698","volume":"13","author":"Y Zhong","year":"2023","unstructured":"Zhong, Y. et al. Suppression of alpha-tubulin acetylation potentiates therapeutic efficacy of eribulin in liver cancer. Am. J. Cancer Res. 13, 5698\u20135718 (2023).","journal-title":"Am. J. Cancer Res."},{"key":"48984_CR19","doi-asserted-by":"publisher","first-page":"D1425","DOI":"10.1093\/nar\/gkac959","volume":"51","author":"Y Han","year":"2023","unstructured":"Han, Y. et al. TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. 51, D1425\u2013D1431 (2023).","journal-title":"Nucleic Acids Res."},{"key":"48984_CR20","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/bioinformatics\/btab003","volume":"37","author":"J Alquicira-Hernandez","year":"2021","unstructured":"Alquicira-Hernandez, J. & Powell, J. E. Nebulosa recovers single-cell gene expression signals by kernel density estimation. Bioinformatics 37, 2485\u20132487 (2021).","journal-title":"Bioinformatics"},{"key":"48984_CR21","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"48984_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s41590-025-02202-x","volume":"26","author":"EM Steinert","year":"2025","unstructured":"Steinert, E. M. et al. Mitochondrial respiration is necessary for CD8\u2009+\u2009T cell proliferation and cell fate. Nat. Immunol. 26, 1267\u20131274 (2025).","journal-title":"Nat. Immunol."},{"key":"48984_CR23","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.ccell.2025.06.020","volume":"43","author":"MM Chen","year":"2025","unstructured":"Chen, M. M. et al. Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer. Cancer Cell. 43, 1656\u20131676e10 (2025).","journal-title":"Cancer Cell."},{"key":"48984_CR24","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-24-2449","volume":"31","author":"B Ra","year":"2025","unstructured":"Ra, B. et al. XMT-2056, a HER2-directed STING agonist antibody-drug conjugate, induces innate antitumor immune responses by acting on cancer cells and tumor-resident immune cells. Clin. Cancer Res. 31, 1766 (2025).","journal-title":"Clin. Cancer Res."},{"key":"48984_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ccell.2024.11.008","volume":"43","author":"Z Yang","year":"2025","unstructured":"Yang, Z. et al. Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1. Cancer Cell. 43, 86\u2013102e10 (2025).","journal-title":"Cancer Cell."},{"key":"48984_CR26","doi-asserted-by":"publisher","first-page":"107461","DOI":"10.1016\/j.vph.2024.107461","volume":"158","author":"Z Jafri","year":"2025","unstructured":"Jafri, Z. et al. Interplay between CD28 and PD-1 in T cell immunotherapy. Vasc. Pharmacol. 158, 107461 (2025).","journal-title":"Vasc. Pharmacol."},{"key":"48984_CR27","doi-asserted-by":"publisher","first-page":"103570","DOI":"10.1016\/j.jpet.2025.103570","volume":"392","author":"Q Mao","year":"2025","unstructured":"Mao, Q. et al. Enhanced efficiency of MHC class II tumor neoantigen vaccines with a novel CD4\u2009+\u2009T-cell helper epitope. J. Pharmacol. Exp. Ther. 392, 103570 (2025).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"48984_CR28","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1158\/0008-5472.CAN-24-4383","volume":"85","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Tumor-specific MHC-II activates CD4\u2009+\u2009and CD8\u2009+\u2009T cells in head and neck squamous cell carcinoma to boost immunotherapy efficacy. Cancer Res. 85, 3258\u20133274 (2025).","journal-title":"Cancer Res."},{"key":"48984_CR29","doi-asserted-by":"publisher","first-page":"216122","DOI":"10.1016\/j.canlet.2023.216122","volume":"559","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. Cancer Lett. 559, 216122 (2023).","journal-title":"Cancer Lett."},{"key":"48984_CR30","doi-asserted-by":"publisher","first-page":"101434","DOI":"10.1016\/j.jhepr.2025.101434","volume":"7","author":"S Pai","year":"2025","unstructured":"Pai, S. et al. The association between stage migration and overall survival after radiation-based therapies in patients with hepatocellular carcinoma. JHEP Rep.  7, 101434 (2025).","journal-title":"JHEP Rep."},{"key":"48984_CR31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","volume":"261","author":"P Tabrizian","year":"2015","unstructured":"Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M. & Roayaie, S. Recurrence of hepatocellular cancer after resection: Patterns, treatments, and prognosis. Ann. Surg. 261, 947\u2013955 (2015).","journal-title":"Ann. Surg."},{"key":"48984_CR32","doi-asserted-by":"publisher","first-page":"113844","DOI":"10.1016\/j.addr.2021.113844","volume":"176","author":"Q Xiao","year":"2021","unstructured":"Xiao, Q. et al. High-throughput proteomics and AI for cancer biomarker discovery. Adv. Drug Deliv. Rev. 176, 113844 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"48984_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13073-023-01229-9","volume":"15","author":"J Sun","year":"2023","unstructured":"Sun, J. et al. Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome. Genome Med. 15, 75 (2023).","journal-title":"Genome Med."},{"key":"48984_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ccell.2018.12.003","volume":"35","author":"DG Mun","year":"2019","unstructured":"Mun, D. G. et al. Proteogenomic characterization of human early-onset gastric cancer. Cancer Cell. 35, 111\u2013124e10 (2019).","journal-title":"Cancer Cell."},{"key":"48984_CR35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","volume":"187","author":"Q Liu","year":"2024","unstructured":"Liu, Q. et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell 187, 184\u2013203e28 (2024).","journal-title":"Cell"},{"key":"48984_CR36","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1159\/000544966","volume":"14","author":"WJ Zheng","year":"2025","unstructured":"Zheng, W. J. et al. 18F-FDG PET\/CT predicts the prognosis of patients with hepatocellular carcinoma undergoing liver transplantation. Liver Cancer. 14, 518\u2013538 (2025).","journal-title":"Liver Cancer"},{"key":"48984_CR37","doi-asserted-by":"publisher","first-page":"215595","DOI":"10.1016\/j.canlet.2022.215595","volume":"533","author":"Y Yao","year":"2022","unstructured":"Yao, Y. et al. HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1\/RBL2\/c-myc axis. Cancer Lett. 533, 215595 (2022).","journal-title":"Cancer Lett."},{"key":"48984_CR38","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1158\/1078-0432.CCR-23-2975","volume":"30","author":"C Guarducci","year":"2024","unstructured":"Guarducci, C. et al. Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor-positive breast cancer. Clin. Cancer Res.  30, 1889\u20131905 (2024).","journal-title":"Clin. Cancer Res."},{"key":"48984_CR39","doi-asserted-by":"publisher","first-page":"1714314","DOI":"10.3389\/fimmu.2026.1714314","volume":"17","author":"J Li","year":"2026","unstructured":"Li, J. et al. Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: Implications for postoperative recurrence risk. Front. Immunol. 17, 1714314 (2026).","journal-title":"Front. Immunol."},{"key":"48984_CR40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jhep.2021.08.029","volume":"76","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Intratumoral stem-like CCR4\u2009+\u2009regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. J. Hepatol. 76, 148\u2013159 (2022).","journal-title":"J. Hepatol."},{"key":"48984_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3892\/ijmm.2026.5729","volume":"57","author":"XM Chen","year":"2026","unstructured":"Chen, X. M. et al. ZG16B: a key regulator of tumor progression and immune microenvironment modulation in cancer (review). Int. J. Mol. Med. 57, 58 (2026).","journal-title":"Int. J. Mol. Med."},{"key":"48984_CR42","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1038\/ncomms6696","volume":"5","author":"S Zou","year":"2014","unstructured":"Zou, S. et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 5, 5696 (2014).","journal-title":"Nat. Commun."},{"key":"48984_CR43","doi-asserted-by":"publisher","DOI":"10.1159\/000549355","author":"J Li","year":"2025","unstructured":"Li, J. et al. Rechallenge with immune checkpoint inhibitors in patients with hepatocellular carcinoma: A narrative review. Liver Cancer. https:\/\/doi.org\/10.1159\/000549355 (2025).","journal-title":"Liver Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48984-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48984-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48984-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:03:23Z","timestamp":1781870603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48984-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48984"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48984-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors agreed on the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"19112"}}